Video

Dr. Ribeiro on Criteria for Determining Borderline Resectability in Pancreatic Cancer

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer is borderline resectable.

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer has borderline resectable disease.

The definition of “borderline resectable” is somewhat subjective, says Ribeiro, as it varies from institution to institution. However, collaborative efforts between surgeons and medical oncologists, as well as consensus guidelines, are helping to standardize the criteria for borderline resectable disease.

Patients with borderline resectable disease typically have a lot of tumor contact with the vein or some contact with the artery, which prevents surgeons from seeing a clear tissue plane on those blood vessels, explains Ribeiro. Generally, the majority of patients with borderline resectable disease will not have an R0 resection if they’re taken to surgery. Those patients will have a higher risk of residual disease after surgery. Therefore, instead of taking patients to surgery and running the risk of heavy residual disease, patients with borderline resectable disease are given neoadjuvant therapy, concludes Ribeiro.

Related Videos
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University